Recent Company News

• 07:08 AM ET May 22, 2026
  

  BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (1.00a, 0.00)

• 07:01 AM ET May 22, 2026
  

  BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

• 07:01 AM ET May 20, 2026
  

  BioLineRx to Report First Quarter 2026 Results on May 27, 2026

• 07:07 AM ET May 19, 2026
  

  BioLineRx, Hemispherian report promising preclinical results supporting Phase 1/2a trial of GLIX1 in recurrent GBM and high-grade gliomas (1.00a, 0.00)

• 07:00 AM ET May 19, 2026
  

  BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts

• 07:04 AM ET Apr 28, 2026
  

  BioLineRx and Hemispherian announce first patient dosed in Phase 1/2a study of GLIX1 for the treatment of GBM (1.00a, 0.00)

• 07:00 AM ET Apr 28, 2026
  

  BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)